Literature DB >> 27849590

Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.

Xinyi Jiang1, Sergio Fitch2, Christine Wang2, Christy Wilson3, Jianfeng Li1, Gerald A Grant3, Fan Yang4,2.   

Abstract

Glioblastoma multiforme (GBM) is one of the most intractable of human cancers, principally because of the highly infiltrative nature of these neoplasms. Tracking and eradicating infiltrating GBM cells and tumor microsatellites is of utmost importance for the treatment of this devastating disease, yet effective strategies remain elusive. Here we report polymeric nanoparticle-engineered human adipose-derived stem cells (hADSCs) overexpressing tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as drug-delivery vehicles for targeting and eradicating GBM cells in vivo. Our results showed that polymeric nanoparticle-mediated transfection led to robust up-regulation of TRAIL in hADSCs, and that TRAIL-expressing hADSCs induced tumor-specific apoptosis. When transplanted in a mouse intracranial xenograft model of patient-derived glioblastoma cells, hADSCs exhibited long-range directional migration and infiltration toward GBM tumor. Importantly, TRAIL-overexpressing hADSCs inhibited GBM growth, extended survival, and reduced the occurrence of microsatellites. Repetitive injection of TRAIL-overexpressing hADSCs significantly prolonged animal survival compared with single injection of these cells. Taken together, our data suggest that nanoparticle-engineered TRAIL-expressing hADSCs exhibit the therapeutically relevant behavior of "seek-and-destroy" tumortropic migration and could be a promising therapeutic approach to improve the treatment outcomes of patients with malignant brain tumors.

Entities:  

Keywords:  TRAIL; adipose-derived stem cells; glioblastoma; nanoparticle; tumor microsatellites

Mesh:

Substances:

Year:  2016        PMID: 27849590      PMCID: PMC5137687          DOI: 10.1073/pnas.1615396113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Immunomodulatory neural stem cells for brain tumour therapy.

Authors:  Jeffrey J Yu; Xiaonan Sun; Xiangpeng Yuan; Jang-Won Lee; Evan Y Snyder; John S Yu
Journal:  Expert Opin Biol Ther       Date:  2006-12       Impact factor: 4.388

2.  Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Authors:  Navid Redjal; Yanni Zhu; Khalid Shah
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

3.  Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells.

Authors:  Tugba Bagci-Onder; Wanlu Du; Jose-Luiz Figueiredo; Jordi Martinez-Quintanilla; Khalid Shah
Journal:  Brain       Date:  2015-04-23       Impact factor: 13.501

Review 4.  TRAIL and apoptosis induction by TNF-family death receptors.

Authors:  Shulin Wang; Wafik S El-Deiry
Journal:  Oncogene       Date:  2003-11-24       Impact factor: 9.867

Review 5.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.

Authors:  S Wang
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

6.  Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles.

Authors:  Fan Yang; Seung-Woo Cho; Sun Mi Son; Said R Bogatyrev; Deepika Singh; Jordan J Green; Ying Mei; Sohyun Park; Suk Ho Bhang; Byung-Soo Kim; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-05       Impact factor: 11.205

7.  Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.

Authors:  Stephen T Keir; Henry S Friedman; David A Reardon; Darell D Bigner; Lloyd A Gray
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

8.  In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.

Authors:  Brian D Brown; Giovanni Sitia; Andrea Annoni; Ehud Hauben; Lucia Sergi Sergi; Anna Zingale; Maria Grazia Roncarolo; Luca G Guidotti; Luigi Naldini
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 9.  Patient-derived xenograft models: an emerging platform for translational cancer research.

Authors:  Manuel Hidalgo; Frederic Amant; Andrew V Biankin; Eva Budinská; Annette T Byrne; Carlos Caldas; Robert B Clarke; Steven de Jong; Jos Jonkers; Gunhild Mari Mælandsmo; Sergio Roman-Roman; Joan Seoane; Livio Trusolino; Alberto Villanueva
Journal:  Cancer Discov       Date:  2014-07-15       Impact factor: 39.397

10.  Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts.

Authors:  Simone Pacioni; Quintino Giorgio D'Alessandris; Stefano Giannetti; Liliana Morgante; Ivana De Pascalis; Valentina Coccè; Arianna Bonomi; Luisa Pascucci; Giulio Alessandri; Augusto Pessina; Maria Laura Falchetti; Roberto Pallini
Journal:  Stem Cell Res Ther       Date:  2015-10-06       Impact factor: 6.832

View more
  26 in total

1.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

2.  Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.

Authors:  Eggehard Holler; Tao Sun; Rameshwar Patil; Anna Galstyan; Dmytro Klymyshyn; Hui Ding; Alexandra Chesnokova; Webster K Cavenee; Frank B Furnari; Vladimir A Ljubimov; Ekaterina S Shatalova; Shawn Wagner; Debiao Li; Adam N Mamelak; Serguei I Bannykh; Chirag G Patil; Jeremy D Rudnick; Jethro Hu; Zachary B Grodzinski; Arthur Rekechenetskiy; Vida Falahatian; Alexander V Lyubimov; Yongmei L Chen; Lai S Leoh; Tracy R Daniels-Wells; Manuel L Penichet; Alexander V Ljubimov; Keith L Black; Julia Y Ljubimova
Journal:  Cancer Res       Date:  2019-01-18       Impact factor: 12.701

Review 3.  Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Authors:  Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler
Journal:  Adv Drug Deliv Rev       Date:  2017-06-10       Impact factor: 15.470

4.  Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences.

Authors:  Cesar A Garcia; Adip G Bhargav; Mieu Brooks; Paola Suárez-Meade; Sujan K Mondal; Natanael Zarco; Karim ReFaey; Mark Jentoft; Erik H Middlebrooks; Matija Snuderl; Anna Carrano; Hugo Guerrero-Cazares; Paula Schiapparelli; Rachel Sarabia-Estrada; Alfredo Quiñones-Hinojosa
Journal:  Mol Cancer Ther       Date:  2021-08-31       Impact factor: 6.009

Review 5.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 6.  Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy.

Authors:  Pedro P G Guimarães; Stephanie Gaglione; Tomasz Sewastianik; Ruben D Carrasco; Robert Langer; Michael J Mitchell
Journal:  ACS Nano       Date:  2018-02-06       Impact factor: 15.881

Review 7.  Engineered stem cells targeting multiple cell surface receptors in tumors.

Authors:  Sanam L Kavari; Khalid Shah
Journal:  Stem Cells       Date:  2019-08-21       Impact factor: 6.277

Review 8.  Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.

Authors:  Hannah J Vaughan; Jordan J Green; Stephany Y Tzeng
Journal:  Adv Mater       Date:  2019-06-20       Impact factor: 30.849

9.  Targeting Tumor Hypoxia Using Nanoparticle-engineered CXCR4-overexpressing Adipose-derived Stem Cells.

Authors:  Xinyi Jiang; Christine Wang; Sergio Fitch; Fan Yang
Journal:  Theranostics       Date:  2018-02-02       Impact factor: 11.556

Review 10.  Overcoming delivery barriers in immunotherapy for glioblastoma.

Authors:  Yuan Rui; Jordan J Green
Journal:  Drug Deliv Transl Res       Date:  2021-05-30       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.